The Claim
Inhibition of myostatin through antibody treatment or genetic deletion reduces bone erosion in mouse models of rheumatoid arthritis, including hTNFtg and K/BxN serum-transfer models, without eliminating inflammation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Blocking myostatin using antibodies or genetic methods reduces bone damage in mice with rheumatoid arthritis, while inflammation remains unchanged.
See the scientific wording
Inhibition of myostatin via antibody treatment or genetic deletion reduces bone erosion in mouse models of rheumatoid arthritis, including hTNFtg and K/BxN serum-transfer models, without eliminating inflammation.
Myostatin binds to receptors on bone-resorbing cells, triggering a chain of signals that turns on a key gene regulator, which forces these cells to mature and break down bone tissue. Blocking myostatin stops this chain, so bone breaks down less, even when joint swelling continues.
What the research says
1 studyBlocking myostatin in mice with arthritis stops their bones from getting damaged, even though their joints are still swollen and inflamed — meaning myostatin specifically hurts bones, not just causes inflammation.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.